H.R. 3537 - 117th Congress (2021-2022) - Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities to facilitate patients' access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.

HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases.

The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases.

Text (5)

December 9, 2021

December 8, 2021

December 8, 2021

May 25, 2021

Actions (24)

Show Only Major Actions

12/23/2021

Became Public Law No: 117-79.

12/23/2021

Signed by President.

12/23/2021

Presented to President.

12/17/2021

Message on Senate action sent to the House.

12/16/2021

Passed Senate without amendment by Voice Vote. (consideration: CR S9242)

12/16/2021

Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.(consideration: CR S9242)

12/09/2021

Received in the Senate, read twice.

12/08/2021

Motion to reconsider laid on the table Agreed to without objection.

12/08/2021

On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 423 - 3 (Roll no. 415). (text: CR H7509-7511)

12/08/2021

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 423 - 3 (Roll no. 415).(text: CR H7509-7511)

12/08/2021

Considered as unfinished business. (consideration: CR H7535-7536)

12/08/2021

At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

12/08/2021

DEBATE - The House proceeded with forty minutes of debate on H.R. 3537.

12/08/2021

Considered under suspension of the rules. (consideration: CR H7509-7514)

12/08/2021

Mr. Pallone moved to suspend the rules and pass the bill, as amended.

12/08/2021

Placed on the Union Calendar, Calendar No. 148.

12/08/2021

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-207.

11/17/2021

Ordered to be Reported (Amended) by Voice Vote.

11/17/2021

Committee Consideration and Mark-up Session Held.

11/04/2021

Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .

11/04/2021

Subcommittee Consideration and Mark-up Session Held.

05/26/2021

Referred to the Subcommittee on Health.

05/25/2021

Referred to the House Committee on Energy and Commerce.

05/25/2021

Introduced in House

Public Record

Record Updated

Mar 8, 2023 8:26:26 PM